Skip to main content

NICE IDs

11/10/2021
ID1393: Ponesimod for treating relapsing multiple sclerosis
11/10/2021
ID1573: Midostaurin for treating advanced systemic mastocytosis
11/10/2021
ID3826: Empagliflozin for treating chronic heart failure with reduced ejection fraction
11/10/2021
ID3741: Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer
11/10/2021
ID3866: Dapagliflozin for treating chronic kidney disease
11/10/2021
ID2692: Bimekizumab for treating moderate to severe chronic plaque psoriasis
11/10/2021
ID1620: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma
11/10/2021
ID1585: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490)
11/10/2021
ID3942: Sacituzumab govitecan for treating metastatic or unresectable triple-negative breast cancer after 2 or more therapies
11/10/2021
ID3777: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492)
11/10/2021
ID1630: Liraglutide for managing obesity in people aged 12 to 17
11/10/2021
ID1590: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over
11/10/2021
ID1483: Roxadustat for treating anaemia in people with chronic kidney disease
11/10/2021
ID3839: Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer
11/10/2021
ID1570: Odevixibat for treating progressive familial intrahepatic cholestasis
11/10/2021
ID1065: Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
11/10/2021
ID3842: Relugolix with oestradiol and norethisterone acetate for treating uterine fibroids
11/10/2021
ID3764: Setmelanotide for treating obesity caused by LEPR or POMC deficiency
11/10/2021
ID1676: Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer
01/06/2021
ID3835: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
Follow AWTTC: